PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-109.95%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
62.96%
Operating income growth of 62.96% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
53.00%
Net income growth of 53.00% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
52.84%
EPS growth of 52.84% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
52.84%
Diluted EPS growth of 52.84% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.82%
OCF growth of 18.82% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
18.82%
FCF growth of 18.82% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-253.14%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-253.14%
Negative 5Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-34.55%
Negative 3Y OCF/share CAGR while Biotechnology median is 18.80%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
-2662.04%
Negative 10Y net income/share CAGR vs. Biotechnology median of 15.02%. Seth Klarman might see a fundamental problem if peers maintain growth.
-2662.04%
Negative 5Y CAGR while Biotechnology median is 25.33%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
63.01%
3Y net income/share CAGR > 1.5x Biotechnology median of 32.56%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
-1507.60%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-1507.60%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-84.19%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.23%
Negative BV/share change while Biotechnology median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-65.79%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.